COCH predicts survival and adjuvant TACE response in patients with HCC

Wang,Chen; Ding,Zhi-Wen; Zheng,Cheng-Gang; Wang,Siyuan; Li,Zhi-Heng; Zhang,Zi-Mu; Pan,Jian; Wang,Jian; Yang,Chun

doi:10.3892/ol.2021.12536

COCH predicts survival and adjuvant TACE response in patients with HCC

Authors:
- Chen Wang
- Zhi-Wen Ding
- Cheng-Gang Zheng
- Siyuan Wang
- Zhi-Heng Li
- Zi-Mu Zhang
- Jian Pan
- Jian Wang
- Chun Yang
View Affiliations

Affiliations: Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, Jiangsu 215025, P.R. China, Department of Hepatobiliary Surgery, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 201805, P.R. China, Department of Hyperbaric Medicine, Changhai Hospital, Naval Medical University, Shanghai 200433, P.R. China, Suzhou Institute of Drug Control, Suzhou, Jiangsu 215031, P.R. China
Published online on: February 10, 2021 https://doi.org/10.3892/ol.2021.12536
Article Number: 275
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to measure the expression of Cochlin (COCH) and analyze its association with survival, recurrence and the benefits from adjuvant transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) following hepatectomy. Patients with high COCH expression levels had a poorer prognosis in terms of overall and disease‑free survival rate compared with those with low COCH expression levels. Further analysis revealed that patients with low COCH expression who received TACE experienced markedly lower early recurrence rates compared with those who did not receive TACE. However, patients with high COCH expression with and without adjuvant TACE after resection experienced no difference in disease recurrence rates. The expression of COCH was found to be associated with hepatitis B virus infection, portal vein tumor thrombosis and Barcelona Clinic Liver Cancer stage in HCC. Therefore, the findings of the present study indicated that clinical detection of COCH expression may help estimate the prognosis of patients with HCC, as well as determine whether to administer TACE after surgery to prevent recurrence.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Bruix J and Sherman M; American Association for the Study of Liver Diseases, : Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
3	Tabrizian P, Jibara G, Shrager B, Schwartz M and Roayaie S: Recurrence of hepatocellular cancer after resection: Patterns, treatments, and prognosis. Ann Surg. 261:947–955. 2015. View Article : Google Scholar : PubMed/NCBI
4	Forner A, Reig M and Bruix J: Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
5	Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, et al: Asia-pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int. 11:317–370. 2017. View Article : Google Scholar : PubMed/NCBI
6	Chan SL, Mo FK, Johnson PJ, Liem GS, Chan TC, Poon MC, Ma BB, Leung TW, Lai PB, Chan AT, et al: Prospective validation of the Chinese University prognostic index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol. 26:340–347. 2011. View Article : Google Scholar : PubMed/NCBI
7	Yang B, Zheng B, Yang M, Zeng Z, Yang F, Pu J, Li C and Liao Z: Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona clinic liver cancer stage B hepatocellular carcinoma. Hepatol Int. 12:417–428. 2018. View Article : Google Scholar : PubMed/NCBI
8	Marquardt JU, Galle PR and Teufel A: Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. J Hepatol. 56:267–275. 2012. View Article : Google Scholar : PubMed/NCBI
9	Chance MR, Chang J, Liu S, Gokulrangan G, Chen DH, Lindsay A, Geng R, Zheng QY and Alagramam K: Proteomics, bioinformatics and targeted gene expression analysis reveals up-regulation of cochlin and identifies other potential biomarkers in the mouse model for deafness in Usher syndrome type 1F. Hum Mol Genet. 19:1515–1527. 2010. View Article : Google Scholar : PubMed/NCBI
10	Ikezono T, Matsumura T, Matsuda H, Shikaze S, Saitoh S, Shindo S, Hasegawa S, Oh SH, Hagiwara Y, Ogawa Y, et al: The diagnostic performance of a novel ELISA for human CTP (Cochlin-tomoprotein) to detect perilymph leakage. PLoS One. 13:e01914982018. View Article : Google Scholar : PubMed/NCBI
11	Jung J, Kim HS, Lee MG, Yang EJ and Choi JY: Novel COCH p.V123E mutation, causative of DFNA9 sensorineural hearing loss and vestibular disorder, shows impaired cochlin post-translational cleavage and secretion. Hum Mutat. 36:1168–1175. 2015. View Article : Google Scholar : PubMed/NCBI
12	Nyström A, Bornert O, Kühl T, Gretzmeier C, Thriene K, Dengjel J, Pfister-Wartha A, Kiritsi D and Bruckner-Tuderman L: Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa. Proc Natl Acad Sci USA. 115:E705–E714. 2018. View Article : Google Scholar : PubMed/NCBI
13	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
14	Suman A, Barnes DS, Zein NN, Levinthal GN, Connor JT and Carey WD: Predicting outcome after cardiac surgery in patients with cirrhosis: A comparison of Child-Pugh and MELD scores. Clin Gastroenterol Hepatol. 2:719–723. 2004. View Article : Google Scholar : PubMed/NCBI
15	Wang K, Liu J, Yan ZL, Li J, Shi LH, Cong WM, Xia Y, Zou QF, Xi T, Shen F, et al: Overexpression of aspartyl-(asparaginyl)- beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology. 52:164–173. 2010. View Article : Google Scholar : PubMed/NCBI
16	Dong LW, Hou YJ, Tan YX, Tang L, Pan YF, Wang M and Wang HY: Prognostic significance of Beclin 1 in intrahepatic cholangiocellular carcinoma. Autophagy. 7:1222–1229. 2011. View Article : Google Scholar : PubMed/NCBI
17	Wang Q, Tan YX, Ren YB, Dong LW, Xie ZF, Tang L, Cao D, Zhang WP, Hu HP and Wang HY: Zinc finger protein ZBTB20 expression is increased in hepatocellular carcinoma and associated with poor prognosis. BMC Cancer. 11:2712011. View Article : Google Scholar : PubMed/NCBI
18	Bas A, Forsberg G, Hammarström S and Hammarström ML: Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes. Scand J Immunol. 59:566–573. 2004. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR and Heimbach JK: Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice guidance by the american association for the study of liver diseases. Hepatology. 68:723–750. 2018. View Article : Google Scholar : PubMed/NCBI
21	Kim JM, Lee SH, Shin WY, Lee KY, Kim JM and Ahn SI: Intrahepatic recurrence of single nodular hepatocellular carcinoma after surgical resection: An analysis by segmental distribution. ANZ J Surg. 88:E840–E844. 2018. View Article : Google Scholar : PubMed/NCBI
22	Wang K, Liu G, Li J, Yan Z, Xia Y, Wan X, Ji Y, Lau WY, Wu M and Shen F: Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: A prospective cohort study. Eur J Surg Oncol. 41:236–242. 2015. View Article : Google Scholar : PubMed/NCBI
23	Huang L, Li J, Yan J, Cao J, Liu C, Zhang X, Wu M and Yan Y: Early recurrence after curative resection in oligonodular hepatocellular carcinoma. Hepatogastroenterology. 60:28–31. 2013.PubMed/NCBI
24	Feng AL, Zhu JK, Yang Y, Wang YD, Liu FY, Zhu M and Liu CZ: Repeated postoperative adjuvant TACE after curative hepatectomy improves outcomes of patients with HCC. Minim Invasive Ther Allied Technol. 1–6. Dec 27–2019.(Epub ahead of print). doi: 10.1080/13645706.2019.1707689. View Article : Google Scholar : PubMed/NCBI
25	Chen J, Huang J, Chen M, Yang K, Chen J, Wang J, Xu L, Zhou Z and Zhang Y: Transcatheter arterial chemoembolization (TACE) versus hepatectomy in hepatocellular carcinoma with macrovascular invasion: A meta-analysis of 1683 patients. J Cancer. 8:2984–2991. 2017. View Article : Google Scholar : PubMed/NCBI
26	Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 37:429–442. 2003. View Article : Google Scholar : PubMed/NCBI
27	Lencioni R, de Baere T, Soulen MC, Rilling WS and Geschwind JF: Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 64:106–116. 2016. View Article : Google Scholar : PubMed/NCBI
28	Oliveri RS, Wetterslev J and Gluud C: Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. CD0047872011.PubMed/NCBI
29	Forner A, Llovet JM and Bruix J: Chemoembolization for intermediate HCC: Is there proof of survival benefit? J Hepatol. 56:984–986. 2012. View Article : Google Scholar : PubMed/NCBI
30	Farinati F, Giacomin A, Vanin V, Giannini E and Trevisani F: TACE treatment in hepatocellular carcinoma: What should we do now? J Hepatol. 57:221–222. 2012. View Article : Google Scholar : PubMed/NCBI
31	Li KW, Li X, Wen TF and Lu WS: The effect of postoperative TACE on prognosis of HCC: An update. Hepatogastroenterology. 60:248–251. 2013.PubMed/NCBI
32	Zhang Y, Chen SW, Liu LL, Yang X, Cai SH and Yun JP: A model combining TNM stage and tumor size shows utility in predicting recurrence among patients with hepatocellular carcinoma after resection. Cancer Manag Res. 10:3707–3715. 2018. View Article : Google Scholar : PubMed/NCBI
33	Li L, Ikezono T, Watanabe A, Shindo S, Pawankar R and Yagi T: Expression of full-length Cochlin p63s is inner ear specific. Auris Nasus Larynx. 32:219–223. 2005. View Article : Google Scholar : PubMed/NCBI
34	Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A and Bolondi L: The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol. 67:173–183. 2017. View Article : Google Scholar : PubMed/NCBI
35	Miksad RA, Ogasawara S, Xia F, Fellous M and Piscaglia F: Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: The LiverT study. BMC Cancer. 19:7952019. View Article : Google Scholar : PubMed/NCBI